Skip to content

7 Biotech Penny Stocks On The Verge Of Clinical Trial Victory

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks.

This is a good time to remind you of all the reasons you shouldn’t buy biotech penny stocks. While many of these companies may claim advanced clinical data and whatnot, the reality is that many, if not most players in this field, will fail. That’s just the harsh reality of this business.

To mitigate the obvious risks associated with this subsector, I’m only targeting companies that have multiple analyst buy ratings. This doesn’t guarantee anything but at least it’s something. With that, here are the biotech penny stocks to consider.

This post appeared first on InvestorPlace.